IPO - rYojbaba Co., Ltd.

Add to your watchlist
Back to List of IPO Filings

Form Type: F-1/A

Filing Date: 2025-05-08

Corporate Action: Ipo

Type: New

Accession Number: 000164117225009218

Filing Summary: Ryojbaba Co., Ltd. is conducting an initial public offering (IPO) of 1,250,000 common shares with an anticipated price range of $4.00 to $5.00 per share. This filing represents a pre-effective amendment to their registration statement under the Securities Act of 1933, indicating that the securities may be offered on a delayed or continuous basis. The company is aiming for a listing on either the NYSE American or The Nasdaq under the symbol 'RYOJ'. As of now, there hasn't been a public market for Ryojbaba's shares, and if the IPO succeeds, the controlling shareholder Ryoji Baba will hold approximately 71.3% of the company’s voting power, enabling him to influence shareholder decisions significantly. Ryojbaba focuses on alleviating work-related stress through consulting and health services and reported revenues of approximately $11.6 million for 2024. The business operates 28 osteopathic clinics and two beauty salons, with significant revenues generated from health services.

Additional details:

Common Shares Offered: 1250000


Ipo Price Range: $4.00 - $5.00


Representative Warrants: 87500


Exercise Price Rep Warrants: $5.00


Proceeds Before Expenses: 4597500


Voting Power After Offering: 71.3%


Form Type: F-1/A

Filing Date: 2025-04-22

Corporate Action: Ipo

Type: New

Accession Number: 000164117225005742

Filing Summary: rYojbaba Co., Ltd. is filing a pre-effective amendment to its registration statement on Form F-1 for an initial public offering (IPO) of 1,250,000 common shares with an expected price range of $4.00 to $5.00 per share. The document outlines the objectives of the company, which focuses on mitigating work-related stress through consulting and health services. The company, headquartered in Fukuoka, Japan, currently operates 28 clinics and two beauty salons but has no prior public market for its shares. Ryoji Baba, the CEO, will maintain significant control post-offering, owning approximately 71.3% of voting power if all shares are sold. The filing underscores the intention to list shares on either the NYSE American or The Nasdaq, detailing corporate governance implications as a controlled company. Additionally, the document touches on the risks associated with investing in its shares, emphasizing the need for careful consideration of the proposed offering’s associated risks and economic conditions.

Additional details:

Company Name: RYOJBABA CO., LTD.


Shares Offered: 1250000


Offer Price Range: $4.00 - $5.00


Expected Initial Listing: NYSE American or Nasdaq


Control Voting Power After Offering: 71.3%


Form Type: F-1/A

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225006517

Filing Summary: rYojbaba Co., Ltd. is conducting its initial public offering (IPO) seeking to sell 1,250,000 common shares, no par value, anticipated to be priced between $4.00 and $5.00 per share. The company aims to list its shares on either the NYSE American or The Nasdaq Capital Market under the symbol 'RYOJ'. The registration statement is a pre-effective amendment related to this offering that discusses both the corporate structure and business operations focusing on alleviating work-related stress through consulting and health services. The primary revenue streams include health services, which made up 87% of $10,963,365 in revenues for the fiscal year ended December 31, 2023. The document warns potential investors of the risks associated with the investment and outlines the company’s controlled status post-offering due to significant share ownership by the CEO, Ryoji Baba.

Additional details:

Approximate Date Of Commencement Of Proposed Sale: As soon as practicable after the effective date


Number Of Common Shares Offered: 1,250,000


Initial Public Offering Price Range: $4.00 to $5.00


Exercise Price Of Warrants: $4.00


Representatives Warrants Number: 87,500


Comments

No comments yet. Be the first to comment!